Organovo Holdings Rebrands to VivoSim Labs, Inc.

Organovo Holdings ( (ONVO) ) has provided an update.

On April 24, 2025, Organovo Holdings officially changed its name to VivoSim Labs, Inc., reflecting its strategic shift towards providing technologies that support the FDA’s move away from animal models. VivoSim has emerged from stealth mode to offer innovative NAM models that leverage AI and human organoid models, aiming to disrupt the $10 billion animal testing market by providing more predictive and ethically sound alternatives. This transition is expected to significantly impact the drug development process, potentially reducing clinical trial failures and development costs, while aligning with the FDA’s vision of accelerating drug evaluation and reducing animal use.

More about Organovo Holdings

VivoSim Labs, Inc., formerly known as Organovo Holdings, operates in the biotechnology industry, focusing on providing advanced non-animal testing models for drug discovery and development. The company specializes in liver and intestinal toxicology insights using new approach methodologies (NAM) models, aiming to replace traditional animal testing methods.

YTD Price Performance: -63.04%

Average Trading Volume: 738,833

Technical Sentiment Signal: Strong Buy

Current Market Cap: $3.42M

Find detailed analytics on ONVO stock on TipRanks’ Stock Analysis page.